{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:53:39Z","timestamp":1792601619273,"version":"4.5.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100337"],"award-info":[{"award-number":["82100337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Sodium-glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycemic agents strongly endorsed in the treatment guidelines for heart failure due to their cardioprotective benefits. However, their specific impact of SGLT2 inhibitors on arrhythmias incompletely understood. This systematic review and meta-analysis aimed to comprehensively evaluate the long-term effects of SGLT2 inhibitors on various arrhythmia types.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We systematically searched PubMed, Embase, Web of Science, and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> from database inception to 30 June 2024, to identify randomized controlled clinical trials (RCTs) with a follow-up duration of at least 52\u00a0weeks. The primary outcome of the meta-analysis was atrial fibrillation (AF) or atrial flutter (AFL), and the secondary outcomes included ventricular tachycardia (VT), ventricular fibrillation (VF), and sinus bradycardia. The pooled risk ratios (RRs) with 95% confidence intervals (CIs) were used to estimate the incidence of arrhythmias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-nine RCTs involving 107,770 participants were included. The results of meta-analysis revealed that patients treated with SGLT2 inhibitors had a reduced risk of AF\/AFL compared with placebo (RR 0.86; 95%CI, 0.77\u20130.95; I<jats:sup>2<\/jats:sup> = 0%; P = 0.003). There was no significant difference in the risk of AF\/AFL between the high-dose SGLT2 inhibitors group and the low-dose SGLT2 inhibitors group (RR 0.78; 95%CI, 0.60\u20131.02; I<jats:sup>2<\/jats:sup> = 0%; P = 0.07), although a decreasing trend in the high-dose group was noted. Similarly, no significant differences were found for VT (RR 0.99; 95%CI, 0.81\u20131.22; I<jats:sup>2<\/jats:sup> = 0%; P = 0.96), VF (RR 1.06; 95%CI, 0.73\u20131.54; I<jats:sup>2<\/jats:sup> = 0%; P = 0.75) or sinus bradycardia (RR 1.12; 95%CI, 0.57\u20132.18; I<jats:sup>2<\/jats:sup> = 0%; P = 0.74) between the SGLT2 inhibitors and placebo groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2 inhibitors significantly reduce the risk of AF\/AFL but have no notable impact on the risk of VT, VF, and sinus bradycardia. Additionally, different doses of SGLT2 inhibitors did not statistically influence AF\/AFL incidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/home<\/jats:ext-link>, identifier PROSPERO:CRD42022371089<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1558367","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:53Z","timestamp":1751435573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Peipei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","article-title":"SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-\/-) type 1 diabetic mice","volume":"271","author":"Al-Sharea","year":"2018","journal-title":"Atherosclerosis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"119440","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"113403","DOI":"10.1016\/j.intimp.2024.113403","article-title":"Empagliflozin protects the heart from atrial fibrillation in rats through inhibiting the NF-\u03baB\/HIF-1\u03b1 regulatory axis and atrial remodeling","volume":"143","author":"Badreldin","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial","volume":"32","author":"Bailey","year":"2015","journal-title":"Diabet. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp. Pract."},{"key":"B11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41569-024-01038-6","article-title":"Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications","volume":"21","author":"Bode","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-Week, multicenter, randomized, double-blind, placebo-controlled study with a 28-Week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"B18","unstructured":"Efficacy and safety of sotagliflozin versus glimepiride and placebo in participants with type 2 diabetes mellitus that are taking metformin monotherapy (SOTA-GLIM)"},{"key":"B19","unstructured":"Efficacy and safety of sotagliflozin versus placebo in participants with type 2 diabetes mellitus on background of sulfonylurea alone or with metformin"},{"key":"B20","unstructured":"Efficacy and safety of sotagliflozin versus placebo in participants with type 2 diabetes mellitus who have in adequate glycemic control while taking insulin alone or with other oral antidiabetic agents (SOTA-INS)"},{"key":"B21","unstructured":"Efficacy and safety of sotagliflozin versus placebo in patients with type 2 diabetes mellitus on background of metformin"},{"key":"B22","article-title":"Efficacy safety and tolerability of the combination of tropifexor and licogliflozin and each monotherapy","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","article-title":"Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study","volume":"9","author":"Grunberger","year":"2018","journal-title":"Diabetes Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid."},{"key":"B31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","article-title":"Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes","volume":"16","author":"Karam","year":"2017","journal-title":"Cardiovasc Diabetol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"key":"B34","doi-asserted-by":"publisher","first-page":"619586","DOI":"10.3389\/fendo.2021.619586","article-title":"Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: a systematic review and Meta- analysis of randomized placebo-controlled trials","volume":"12","author":"Li","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2459\/JCM.0000000000001453","article-title":"SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway","volume":"24","author":"Li","year":"2023","journal-title":"J. Cardiovasc Med. Hagerst."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e019274","DOI":"10.1161\/JAHA.120.019274","article-title":"Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction","volume":"10","author":"Lin","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc15-0779","article-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin Add-on to saxagliptin plus metformin in type 2 diabetes","volume":"38","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC","volume":"24","author":"Mcdonagh","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"Mcmurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3390\/ijms18081704","article-title":"The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice","volume":"18","author":"Nakatsu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose Co-Transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/ehf2.15172","article-title":"Implementation of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa-HF registry)","volume":"12","author":"Paolillo","year":"2025","journal-title":"Esc. Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0117567","DOI":"10.1371\/journal.pone.0117567","article-title":"The ER stress-mediated mitochondrial apoptotic pathway and MAPKs modulate tachypacing-induced apoptosis in HL-1 atrial myocytes","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cvr\/cvae095","article-title":"Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF","volume":"120","author":"Trum","year":"2024","journal-title":"Cardiovasc Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15212\/cvia.2023.0028","article-title":"Mechanisms of sodium-glucose cotransporter 2 inhibitors in heart failure","volume":"8","author":"Wei","year":"2023","journal-title":"Cardiovasc. INNOVATIONS Appl."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"B58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/eurheartj\/ehw045","article-title":"Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions","volume":"38","author":"Wong","year":"2017","journal-title":"Eur. Heart J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e045844","DOI":"10.1136\/bmjopen-2020-045844","article-title":"Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes","volume":"11","author":"Yabe","year":"2021","journal-title":"BMJ Open"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"B64","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.hrthm.2017.01.046","article-title":"Increment of late sodium currents in the left atrial myocytes and its potential contribution to increased susceptibility of atrial fibrillation in castrated Male mice","volume":"14","author":"Zhang","year":"2017","journal-title":"Heart rhythm."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1558367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:54Z","timestamp":1751435574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1558367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":66,"alternative-id":["10.3389\/fphar.2025.1558367"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1558367","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"article-number":"1558367"}}